Author Affiliation: Robert E. Fechner Laboratory of Surgical Pathology, University of Virginia Health System, Charlottesville.
In women's health, a remarkable convergence of events in 2001 has produced
new information and direction to foster systematic improvement in cervical
cancer screening. The Atypical Squamous Cells of Undetermined Significance–Low-grade
Squamous Intraepithelial Lesion (ASCUS-LSIL) Triage Study (ALTS), which is
sponsored by the National Cancer Institute, has published several articles
presenting long-awaited data regarding the utility of human papillomavirus
(HPV) testing in the context of the most common forms of cytological abnormality.1-4 These
data supported the effort to revise the Bethesda System terminology used for
reporting results of cervical cytology screening. Both the new Bethesda terminology
and the ALTS data directly influenced management guidelines produced by the
American Society of Colposcopy and Cervical Pathology (ASCCP)–sponsored
Stoler MH. New Bethesda Terminology and Evidence-Based Management Guidelines for Cervical Cytology Findings. JAMA. 2002;287(16):2140–2141. doi:10.1001/jama.287.16.2140
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: